|
Bamifylline
|
DB13203 |
[Bamifylline is a selective A1 adenosine receptor antagonist.] |
|
Strontium cation Sr-89
|
DB14536 |
|
|
Dimethyl carbate
|
DB13204 |
[Dimethyl carbate is used as an insect repellant.] |
|
Teclozan
|
DB13205 |
[Teclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.] |
|
Indium cation In-111
|
DB14535 |
|
|
Chromous sulfate
|
DB14530 |
|
|
Zinc cation
|
DB14532 |
|
|
Lipegfilgrastim
|
DB13200 |
[Lipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology [A32665]. It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia. Since July 2013, lipegfilgrastim is marketed by the EMA as Lonquex for subcutaneously injection, where it is administered once following cytotoxic chemotherapy for each chemotherapy cycle in adult patients being treated with cytotoxic chemotherapy for malignancy. It aims to reduce the duration of neutropenia and the incidence of febrile neutropenia.
Neutropenia and febrile neutropenia (FN) are frequent and potentially fatal complications that occur from myelosuppressive anticancer treatments [A32665]. Severe chemotherapy-induced neutropenia and febrile neutropenia significantly increases the risk for life-threatening infection and sepsis. Granulocyte colony-stimulating factors (G-CSFs) were introduced in the 1980's to the clinical setting to stimulate neutrophil proliferation and differentiation, thereby reducing the duration and severity of chemotherapy-induced neutropenia [A32665]. Lipegfilgrastim is a covalent conjugate of [DB00099] with a single methoxy polyethylene glycol (PEG) molecule via a carbohydrate linker consisting of glycine, N-acetylneuraminic acid and N-acetylgalactosamine [L2441]. The average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449]. PEG moiety protects the active molecule from enzyme degradation, which allows longer half-life of drug and less frequent dosing-schedule in addition to acceptable safety and efficacy profile [A32665].] |
|
Trenonacog alfa
|
DB13201 |
[Human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells.] |
|
Carbonate ion
|
DB14531 |
|
|
Encainide
|
DB01228 |
[All drug products containing encainide hydrochloride. Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.] |
|
Levacetylmethadol
|
DB01227 |
[A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.] |
|
N-(3-Phenyl-2-Sulfanylpropanoyl)Phenylalanylalanine
|
DB02558 |
|
|
S-(N-hydroxy-N-bromophenylcarbamoyl)glutathione
|
DB03889 |
|
|
6-(Octahydro-1h-Indol-1-Ylmethyl)Decahydroquinazoline-2,4-Diamine
|
DB02559 |
|
|
Paclitaxel
|
DB01229 |
[Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.] |
|
Alpha-Adenosine Monophosphate
|
DB03887 |
|
|
D-Phenylalanine
|
DB02556 |
[An essential aromatic amino acid that is a precursor of melanin; dopamine; noradrenalin (norepinephrine), and thyroxine. [PubChem]] |
|
Quetiapine
|
DB01224 |
[Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder.[L8546] Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [Clozapine] and [Olanzapine].[A2189]] |
|
Phosphoramidon
|
DB02557 |
|
